Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 14

1.

Change of tumour characteristics and treatment over time in both arms of the European Randomized study of Screening for Prostate Cancer.

Boevee SJ, Venderbos LD, Tammela TL, Nelen V, Ciatto S, Kwiatkowski M, Páez A, Malavaud B, Hugosson J, Roobol MJ.

Eur J Cancer. 2010 Nov;46(17):3082-9. doi: 10.1016/j.ejca.2010.09.033.

PMID:
21047590
2.

Detection of prostate cancer: the impact of the European Randomized Study of Screening for Prostate Cancer (ERSPC).

Schröder FH.

Can J Urol. 2005 Feb;12 Suppl 1:2-6; discussion 92-3. Review.

PMID:
15780157
3.

Prostate cancer.

Hahnfeld LE, Moon TD.

Med Clin North Am. 1999 Sep;83(5):1231-45, vi. Review.

PMID:
10503062
4.
5.

Prostate-specific antigen doubling time and survival in patients with advanced metastatic prostate cancer.

Loberg RD, Fielhauer JR, Pienta BA, Dresden S, Christmas P, Kalikin LM, Olson KB, Pienta KJ.

Urology. 2003 Dec 29;62 Suppl 1:128-33. Review.

PMID:
14747050
6.

Epilogue: different approaches for prostate cancer screening in the EU?

Schröder FH, Denis L, Roobol MJ.

Eur J Cancer. 2010 Nov;46(17):3120-5. doi: 10.1016/j.ejca.2010.09.038. Review.

PMID:
21047595
7.

[Clinics in prostate cancer].

Sugimura Y.

Rinsho Byori. 2004 Jul;52(7):604-10. Review. Japanese.

PMID:
15344560
8.

Prostate specific antigen recurrence after definitive therapy.

Freedland SJ, Moul JW.

J Urol. 2007 Jun;177(6):1985-91. Review.

PMID:
17509277
9.

[Prostate cancer. Treatment].

Fournier G, Valeri A, Mangin P, Cussenot O.

Ann Urol (Paris). 2004 Oct;38(5):225-58. Review. French.

PMID:
15570706
10.

Prostate cancer: emerging concepts. Part II.

Garnick MB, Fair WR.

Ann Intern Med. 1996 Aug 1;125(3):205-12. Review.

PMID:
8686979
11.
12.

The management of prostate cancer in patients with a rising prostate-specific antigen level.

Fichtner J.

BJU Int. 2000 Jul;86(2):181-90;quiz ii-iii. Review. No abstract available.

13.

American Cancer Society guideline for the early detection of prostate cancer: update 2010.

Wolf AM, Wender RC, Etzioni RB, Thompson IM, D'Amico AV, Volk RJ, Brooks DD, Dash C, Guessous I, Andrews K, DeSantis C, Smith RA; American Cancer Society Prostate Cancer Advisory Committee.

CA Cancer J Clin. 2010 Mar-Apr;60(2):70-98. doi: 10.3322/caac.20066. Epub 2010 Mar 3. Review.

14.

Optimal duration of neoadjuvant androgen withdrawal therapy before radical prostatectomy in clinically confined prostate cancer.

Gleave ME, Goldenberg SL, Jones EC, Bruchovsky N, Kinahan J, Sullivan LD.

Semin Urol Oncol. 1996 May;14(2 Suppl 2):39-45; discussion 46-7. Review.

PMID:
8725890

Supplemental Content

Support Center